Clinical Research Papers:
Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015–16
PDF | HTML | How to cite
Metrics: PDF 991 views | HTML 1592 views | ?
Sivan Sharabi1,2, Ravit Bassal3, Nehemya Friedman1,2, Yaron Drori1,2, Hadar Alter1, Aharona Glatman-Freedman2,3,4, Musa Hindiyeh1,2, Daniel Cohen2, Ella Mendelson1,2, Tamy Shohat2,3 and Michal Mandelboim1,2
1Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
2Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3The Israel Center for Disease Control, Israel Ministry of Health, Tel-Hashomer, Ramat-Gan, Israel
4Department of Family and Community Medicine, New York Medical College, Valhalla, New York, United States
Michal Mandelboim, email: [email protected]
Keywords: influenza B; vaccine; Yamagata; Victoria
Received: August 23, 2017 Accepted: November 29, 2017 Published: December 22, 2017
While infection with influenza A viruses has been extensively investigated, infections with influenza B viruses which are commonly categorized into the highly homologous Victoria and Yamagata lineages, are less studied, despite their considerable virulence. Here we used RT-PCR assays, hemagglutination inhibition assays and antibody titers to determine the levels of influenza B infection. We report of high influenza B Victoria virus prevalence in the 2015–16 winter season in Israel, affecting approximately half of the Israeli population. We further show that the Victoria B virus infected individuals of all ages and that it was present in the country throughout the entire winter season. The vaccine however included the inappropriate Yamagata virus. We propose that a quadrivalent vaccine, that includes both Yamagata and Victoria lineages, should be considered for future influenza vaccination.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.